Barinthus Biotherapeutics (BRNS) Ownership - Who owns Barinthus Biotherapeutics?
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer... Show more
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. BRNS showed earnings on August 07, 2025. You can read more about the earnings report here.